Roche is calling it quits on a late-stage trial of the company’s Huntington’s disease hopeful tominersen, the Swiss drugmaker said on March 22, a blow for sufferers of the rare, debilitating disease with no treatments to stop or reverse it.
Regeneron Launches Phase III COVID-19 Prevention Trial with Antibody Cocktail
Antibodies, Brazil, Chile, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Data Monitoring Committee (DMC), Drug Cocktails, Hospitalized COVID-19 Patients, Interleukin-6 (IL-6), Medical Journals, Mexico, National Institute of Allergy and Infectious Diseases (NIAID), R&D, Science, Secondary Endpoints, United StatesRegeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
Merck’s Keytruda Hits Coprimary Endpoint Early in Colorectal Cancer Trial
Blockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, Colorectal Cancer, Data Monitoring Committee (DMC), Metastatic Colorectal Cancer (mCRC), Overall Survival (OS), Primary Endpoints, Progression-Free Survival (PFS), R&D, TherapeuticsMerck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.
Ipsen decided to temporarily pause dosing in the company’s palovarotene extension studies for patients with fibrodysplasia ossificans progressiva following a recommendation from an Independent Data Monitoring Committee.
Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.